August 07, 2015
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
Aerie reports net loss of $18.8 million for second quarter
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Aerie Pharmaceuticals reported a GAAP net loss of $18.8 million, or $0.73 per share, in the second quarter compared with $11.8 million, or $0.49 per share, in the same quarter of 2014, according to a press release.
The net loss included $18.1 million in operating expenses, which reflected $10.6 million in research and development expenses and $7.5 million in general and administrative expenses. Operating expenses were reported at $9.4 million in the same quarter of 2014.
The increase in operating expenses was primarily attributed to increased clinical activities for Rhopressa, increased non-clinical activities for Roclatan and growth in company operations.